SCH CD-ASTHMA MEDICATION

Illinois General Assembly - Full Text of SB2837

Select Language

×

The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.

Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.

The English language version is always the official and authoritative version of this website.

NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.

Choose Language

English

Afrikaans

Albanian

Arabic

Armenian

Azerbaijani

Basque

Bengali

Bosnian

Catalan

Croatian

Czech

Danish

Dutch

Esperanto

Estonian

Filipino

Finnish

French

Galician

Georgian

German

Greek

Gujarati

Haitian Creole

Hausa

Hawaiian

Hebrew

Hindi

Hungarian

Icelandic

Indonesian

Interlingua

Interlingue

Inuktitut

Irish

Italian

Japanese

Javanese

Kannada

Khmer

Korean

Latin

Latvian

Lithuanian

Luxembourgish

Macedonian

Malagasy

Malayalam

Maltese

Maori

Marathi

Myanmar

Nepali

Norwegian

Odia

Pashto

Punjabi

Romanian

Russian

Samoan

Sango

Sanskrit

Sardinian

Sindhi

Sinhala

Slovak

Slovenian

Somali

Southern Sotho

Spanish

Sundanese

Swahili

Swedish

Tamil

Telugu

Thai

Tigrinya

Tonga

Turkish

Ukrainian

Urdu

Vietnamese

Welsh

Xhosa

Yiddish

Yoruba

Zulu

Powered by
Translate

Close

Illinois General Assembly

Top Navigation Bar

Translate

Learn

Select General Assembly

Search the 104th General Assembly

Enter search terms for legislation, members, committees, or schedules.

ILGA.GOV

LEGISLATION & LAWS

Bills & Resolutions

Public Acts

Illinois Compiled Statutes

Illinois Constitution

Search Legislation

Glossary

Guide

Reports & Inquiry

Legislative Reports

Special Reports

FTP Site

Legislator Lookup

Capitol Complex Phone Numbers

Rules & Regulations

Illinois Register

Administrative Rules

Senate

Members

Schedules

Committees

Request for Remote Testimony

Journals

Transcripts

Rules

Audio/Video

FOIA Information

Senate Employment Opportunities

Media Guidelines

House

Members

Schedules

Committees

Submit testimony for House Committees

Journals

Transcripts

Rules

Audio/Video

FOIA Information

House Employment Opportunities

Log In

Mobile Top Bar

Search the 104th General Assembly

Enter keywords to search the Illinois General Assembly website.

Full Text of SB2837

Home

Legislation

Full Text

SB2837 - 104th General Assembly

Bill Status

Full Text

Votes

Witness Slips

Select Menu

Bill Status

Full Text

Votes

Witness Slips

Printer Friendly Version

Introduced

Senate Amendment 001

Senate Amendment 002

Printer Friendly Version

Introduced

Senate Amendment 001

Senate Amendment 002

Open PDF

104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026
SB2837

Introduced 1/13/2026, by Sen. Adriane Johnson

SYNOPSIS AS INTRODUCED:

105 ILCS 5/22-30

Amends the School Code. In provisions concerning the administration
of asthma medication, epinephrine injectors, opioid antagonists, and
oxygen tanks, provides that "trained personnel" includes athletic coaches
and trainers. Allows a pupil with asthma to self-administer and self-carry
the pupil's asthma medication at a school-sponsored athletic practice or
game. Allows a school nurse or trained personnel to administer
undesignated asthma medication to a person at a school-sponsored athletic
practice or game. Makes a change to provide that a school district, public
school, charter school, or nonpublic school may maintain a supply of
asthma medication in the nurse's office. Requires a school district,
public school, charter school, or nonpublic school to maintain a supply of
asthma medication in a secure location that is accessible before, during,
and after school where a person is most at risk on account of physical
activity. Requires at least one member of an athletic coach's staff at a
school and any athletic trainers at that school to complete the training
curriculum relating to the administration of undesignated asthma
medication.
LRB104 17109 LNS 30528 b
STATE MANDATES ACT MAY REQUIRE REIMBURSEMENT
MAY APPLY

A BILL FOR

SB2837
LRB104 17109 LNS 30528 b
1

AN ACT concerning education.

2

Be it enacted by the People of the State of Illinois,
3
represented in the General Assembly:

4

Section 5.
The School Code is amended by changing Section
5
22-30 as follows:

6

(105 ILCS 5/22-30)
7

Sec. 22-30.
Self-administration and self-carry of asthma
8
medication and epinephrine injectors; administration of
9
undesignated epinephrine injectors; administration of an
10
opioid antagonist; administration of undesignated asthma
11
medication; supply of undesignated oxygen tanks; asthma
12
episode emergency response protocol.
13

(a) For the purpose of this Section only, the following
14
terms shall have the meanings set forth below:
15

"Asthma action plan" means a written plan developed with a
16
pupil's medical provider to help control the pupil's asthma.
17
The goal of an asthma action plan is to reduce or prevent
18
flare-ups and emergency department visits through day-to-day
19
management and to serve as a student-specific document to be
20
referenced in the event of an asthma episode.
21

"Asthma episode emergency response protocol" means a
22
procedure to provide assistance to a pupil experiencing
23
symptoms of wheezing, coughing, shortness of breath, chest

SB2837
- 2 -
LRB104 17109 LNS 30528 b
1
tightness, or breathing difficulty.
2

"Epinephrine injector" includes an auto-injector approved
3
by the United States Food and Drug Administration for the
4
administration of epinephrine and a pre-filled syringe
5
approved by the United States Food and Drug Administration and
6
used for the administration of epinephrine that contains a
7
pre-measured dose of epinephrine that is equivalent to the
8
dosages used in an auto-injector.
9

"Asthma medication" means quick-relief asthma medication,
10
including albuterol or other short-acting bronchodilators,
11
that is approved by the United States Food and Drug
12
Administration for the treatment of respiratory distress.
13
"Asthma medication" includes medication delivered through a
14
device, including a metered dose inhaler with a reusable or
15
disposable spacer or a nebulizer with a mouthpiece or mask.
16

"Athletic coach" means an individual hired by or
17
volunteering for a school district, public school, charter
18
school, or nonpublic school to oversee and direct school
19
athletic teams.

20

"Athletic trainer" means an individual hired by a school
21
district, public school, charter school, or nonpublic school
22
to aid school athletics in the prevention, examination,
23
diagnosis, treatment, and rehabilitation of injuries.

24

"Opioid antagonist" means a drug that binds to opioid
25
receptors and blocks or inhibits the effect of opioids acting
26
on those receptors, including, but not limited to, naloxone

SB2837
- 3 -
LRB104 17109 LNS 30528 b
1
hydrochloride or any other similarly acting drug approved by
2
the U.S. Food and Drug Administration.
3

"Respiratory distress" means the perceived or actual
4
presence of wheezing, coughing, shortness of breath, chest
5
tightness, breathing difficulty, or any other symptoms
6
consistent with asthma. Respiratory distress may be
7
categorized as "mild-to-moderate" or "severe".
8

"School nurse" means a registered nurse working in a
9
school with or without licensure endorsed in school nursing.
10

"Self-administration" means a pupil's discretionary use of
11
his or her prescribed asthma medication or epinephrine
12
injector.
13

"Self-carry" means a pupil's ability to carry his or her
14
prescribed asthma medication or epinephrine injector.
15

"Standing protocol" may be issued by (i) a physician
16
licensed to practice medicine in all its branches, (ii) a
17
licensed physician assistant with prescriptive authority, or
18
(iii) a licensed advanced practice registered nurse with
19
prescriptive authority.
20

"Trained personnel" means any school employee
, athletic
21
coach, athletic trainer,
or volunteer personnel authorized in
22
Sections 10-22.34, 10-22.34a, and 10-22.34b of this Code who
23
has completed training under subsection (g) of this Section to
24
recognize and respond to anaphylaxis, an opioid overdose, or
25
respiratory distress.
26

"Undesignated asthma medication" means asthma medication

SB2837
- 4 -
LRB104 17109 LNS 30528 b
1
prescribed in the name of a school district, public school,
2
charter school, or nonpublic school.
3

"Undesignated epinephrine injector" means an epinephrine
4
injector prescribed in the name of a school district, public
5
school, charter school, or nonpublic school.
6

(b) A school, whether public, charter, or nonpublic, must
7
permit the self-administration and self-carry of asthma
8
medication by a pupil with asthma or the self-administration
9
and self-carry of an epinephrine injector by a pupil, provided
10
that:
11

(1) the parents or guardians of the pupil provide to
12

the school (i) written authorization from the parents or
13

guardians for (A) the self-administration and self-carry
14

of asthma medication or (B) the self-carry of asthma
15

medication or (ii) for (A) the self-administration and
16

self-carry of an epinephrine injector or (B) the
17

self-carry of an epinephrine injector, written
18

authorization from the pupil's physician, physician
19

assistant, or advanced practice registered nurse; and
20

(2) the parents or guardians of the pupil provide to
21

the school (i) the prescription label, which must contain
22

the name of the asthma medication, the prescribed dosage,
23

and the time at which or circumstances under which the
24

asthma medication is to be administered, or (ii) for the
25

self-administration or self-carry of an epinephrine
26

injector, a written statement from the pupil's physician,

SB2837
- 5 -
LRB104 17109 LNS 30528 b
1

physician assistant, or advanced practice registered nurse
2

containing the following information:
3

(A) the name and purpose of the epinephrine
4

injector;
5

(B) the prescribed dosage; and
6

(C) the time or times at which or the special
7

circumstances under which the epinephrine injector is
8

to be administered.
9
The information provided shall be kept on file in the office of
10
the school nurse or, in the absence of a school nurse, the
11
school's administrator.
12

(b-5) A school district, public school, charter school, or
13
nonpublic school may authorize the provision of a
14
student-specific or undesignated epinephrine injector to a
15
student or any personnel authorized under a student's
16
Individual Health Care Action Plan, allergy emergency action
17
plan, or plan pursuant to Section 504 of the federal
18
Rehabilitation Act of 1973 to administer an epinephrine
19
injector to the student, that meets the student's prescription
20
on file.
21

(b-10) The school district, public school, charter school,
22
or nonpublic school may authorize a school nurse or trained
23
personnel to do the following: (i) provide an undesignated
24
epinephrine injector to a student for self-administration only
25
or any personnel authorized under a student's Individual
26
Health Care Action Plan, allergy emergency action plan, plan

SB2837
- 6 -
LRB104 17109 LNS 30528 b
1
pursuant to Section 504 of the federal Rehabilitation Act of
2
1973, or individualized education program plan to administer
3
to the student that meets the student's prescription on file;
4
(ii) administer an undesignated epinephrine injector that
5
meets the prescription on file to any student who has an
6
Individual Health Care Action Plan, allergy emergency action
7
plan, plan pursuant to Section 504 of the federal
8
Rehabilitation Act of 1973, or individualized education
9
program plan that authorizes the use of an epinephrine
10
injector; (iii) administer an undesignated epinephrine
11
injector to any person that the school nurse or trained
12
personnel in good faith believes is having an anaphylactic
13
reaction; (iv) administer an opioid antagonist to any person
14
that the school nurse or trained personnel in good faith
15
believes is having an opioid overdose; (v) provide
16
undesignated asthma medication to a student for
17
self-administration only or to any personnel authorized under
18
a student's Individual Health Care Action Plan or asthma
19
action plan, plan pursuant to Section 504 of the federal
20
Rehabilitation Act of 1973, or individualized education
21
program plan to administer to the student that meets the
22
student's prescription on file; (vi) administer undesignated
23
asthma medication that meets the prescription on file to any
24
student who has an Individual Health Care Action Plan or
25
asthma action plan, plan pursuant to Section 504 of the
26
federal Rehabilitation Act of 1973, or individualized

SB2837
- 7 -
LRB104 17109 LNS 30528 b
1
education program plan that authorizes the use of asthma
2
medication; and (vii) administer undesignated asthma
3
medication to any person that the school nurse or trained
4
personnel believes in good faith is having respiratory
5
distress.
6

(c) The school district, public school, charter school, or
7
nonpublic school must inform the parents or guardians of the
8
pupil, in writing, that the school district, public school,
9
charter school, or nonpublic school and its employees and
10
agents, including a physician, physician assistant, or
11
advanced practice registered nurse providing standing protocol
12
and a prescription for school epinephrine injectors, an opioid
13
antagonist, or undesignated asthma medication, are to incur no
14
liability or professional discipline, except for willful and
15
wanton conduct, as a result of any injury arising from the
16
administration of asthma medication, an epinephrine injector,
17
or an opioid antagonist regardless of whether authorization
18
was given by the pupil's parents or guardians or by the pupil's
19
physician, physician assistant, or advanced practice
20
registered nurse. The parents or guardians of the pupil must
21
sign a statement acknowledging that the school district,
22
public school, charter school, or nonpublic school and its
23
employees and agents are to incur no liability, except for
24
willful and wanton conduct, as a result of any injury arising
25
from the administration of asthma medication, an epinephrine
26
injector, or an opioid antagonist regardless of whether

SB2837
- 8 -
LRB104 17109 LNS 30528 b
1
authorization was given by the pupil's parents or guardians or
2
by the pupil's physician, physician assistant, or advanced
3
practice registered nurse and that the parents or guardians
4
must indemnify and hold harmless the school district, public
5
school, charter school, or nonpublic school and its employees
6
and agents against any claims, except a claim based on willful
7
and wanton conduct, arising out of the administration of
8
asthma medication, an epinephrine injector, or an opioid
9
antagonist regardless of whether authorization was given by
10
the pupil's parents or guardians or by the pupil's physician,
11
physician assistant, or advanced practice registered nurse.
12

(c-5) When a school nurse or trained personnel administers
13
an undesignated epinephrine injector to a person whom the
14
school nurse or trained personnel in good faith believes is
15
having an anaphylactic reaction, administers an opioid
16
antagonist to a person whom the school nurse or trained
17
personnel in good faith believes is having an opioid overdose,
18
or administers undesignated asthma medication to a person whom
19
the school nurse or trained personnel in good faith believes
20
is having respiratory distress, notwithstanding the lack of
21
notice to the parents or guardians of the pupil or the absence
22
of the parents or guardians signed statement acknowledging no
23
liability, except for willful and wanton conduct, the school
24
district, public school, charter school, or nonpublic school
25
and its employees and agents, and a physician, a physician
26
assistant, or an advanced practice registered nurse providing

SB2837
- 9 -
LRB104 17109 LNS 30528 b
1
standing protocol and a prescription for undesignated
2
epinephrine injectors, an opioid antagonist, or undesignated
3
asthma medication, are to incur no liability or professional
4
discipline, except for willful and wanton conduct, as a result
5
of any injury arising from the use of an undesignated
6
epinephrine injector, the use of an opioid antagonist, or the
7
use of undesignated asthma medication, regardless of whether
8
authorization was given by the pupil's parents or guardians or
9
by the pupil's physician, physician assistant, or advanced
10
practice registered nurse.
11

(d) The permission for self-administration and self-carry
12
of asthma medication or the self-administration and self-carry
13
of an epinephrine injector is effective for the school year
14
for which it is granted and shall be renewed each subsequent
15
school year upon fulfillment of the requirements of this
16
Section.
17

(e) Provided that the requirements of this Section are
18
fulfilled, a pupil with asthma may self-administer and
19
self-carry his or her asthma medication or a pupil may
20
self-administer and self-carry an epinephrine injector (i)
21
while in school, (ii) while at a school-sponsored activity,
22
(iii) while under the supervision of school personnel, or (iv)
23
before or after normal school activities, such as while in
24
before-school or after-school care on school-operated
25
property
, at a school-sponsored athletic practice or game,
or
26
while being transported on a school bus.

SB2837
- 10 -
LRB104 17109 LNS 30528 b
1

(e-5) Provided that the requirements of this Section are
2
fulfilled, a school nurse or trained personnel may administer
3
an undesignated epinephrine injector to any person whom the
4
school nurse or trained personnel in good faith believes to be
5
having an anaphylactic reaction (i) while in school, (ii)
6
while at a school-sponsored activity, (iii) while under the
7
supervision of school personnel, or (iv) before or after
8
normal school activities, such as while in before-school or
9
after-school care on school-operated property or while being
10
transported on a school bus. A school nurse or trained
11
personnel may carry undesignated epinephrine injectors on his
12
or her person while in school or at a school-sponsored
13
activity.
14

(e-10) Provided that the requirements of this Section are
15
fulfilled, a school nurse or trained personnel may administer
16
an opioid antagonist to any person whom the school nurse or
17
trained personnel in good faith believes to be having an
18
opioid overdose (i) while in school, (ii) while at a
19
school-sponsored activity, (iii) while under the supervision
20
of school personnel, or (iv) before or after normal school
21
activities, such as while in before-school or after-school
22
care on school-operated property. A school nurse or trained
23
personnel may carry an opioid antagonist on his or her person
24
while in school or at a school-sponsored activity.
25

(e-15) If the requirements of this Section are met, a
26
school nurse or trained personnel may administer undesignated

SB2837
- 11 -
LRB104 17109 LNS 30528 b
1
asthma medication to any person whom the school nurse or
2
trained personnel in good faith believes to be experiencing
3
respiratory distress (i) while in school, (ii) while at a
4
school-sponsored activity, (iii) while under the supervision
5
of school personnel, or (iv) before or after normal school
6
activities, including before-school or after-school care on
7
school-operated property
or at a school-sponsored athletic
8
practice or game
. A school nurse or trained personnel may
9
carry undesignated asthma medication on his or her person
10
while in school or at a school-sponsored activity.
11

(f) The school district, public school, charter school, or
12
nonpublic school may maintain a supply of undesignated
13
epinephrine injectors in any secure location that is
14
accessible before, during, and after school where an allergic
15
person is most at risk, including, but not limited to,
16
classrooms and lunchrooms. A physician, a physician assistant
17
who has prescriptive authority in accordance with Section 7.5
18
of the Physician Assistant Practice Act of 1987, or an
19
advanced practice registered nurse who has prescriptive
20
authority in accordance with Section 65-40 of the Nurse
21
Practice Act may prescribe undesignated epinephrine injectors
22
in the name of the school district, public school, charter
23
school, or nonpublic school to be maintained for use when
24
necessary. Any supply of epinephrine injectors shall be
25
maintained in accordance with the manufacturer's instructions.
26

The school district, public school, charter school, or

SB2837
- 12 -
LRB104 17109 LNS 30528 b
1
nonpublic school shall maintain a supply of an opioid
2
antagonist in any secure location where an individual may have
3
an opioid overdose, unless there is a shortage of opioid
4
antagonists, in which case the school district, public school,
5
charter school, or nonpublic school shall make a reasonable
6
effort to maintain a supply of an opioid antagonist. Unless
7
the school district, public school, charter school, or
8
nonpublic school is able to obtain opioid antagonists without
9
a prescription, a health care professional who has been
10
delegated prescriptive authority for opioid antagonists in
11
accordance with Section 5-23 of the Substance Use Disorder Act
12
shall prescribe opioid antagonists in the name of the school
13
district, public school, charter school, or nonpublic school,
14
to be maintained for use when necessary. Any supply of opioid
15
antagonists shall be maintained in accordance with the
16
manufacturer's instructions.
17

The school district, public school, charter school, or
18
nonpublic school may maintain a supply of asthma medication in
19
any secure location that is accessible before, during, or
20
after school where a person is most at risk, including, but not
21
limited to, a classroom
,
or the nurse's office.
The school
22
district, public school, charter school, or nonpublic school
23
must maintain a supply of asthma medication in a secure
24
location that is accessible before, during, and after school
25
where a person is most at risk on account of physical activity,
26
including, but not limited to, a practice field, track, or

SB2837
- 13 -
LRB104 17109 LNS 30528 b
1
gym.
A physician, a physician assistant who has prescriptive
2
authority under Section 7.5 of the Physician Assistant
3
Practice Act of 1987, or an advanced practice registered nurse
4
who has prescriptive authority under Section 65-40 of the
5
Nurse Practice Act may prescribe undesignated asthma
6
medication in the name of the school district, public school,
7
charter school, or nonpublic school to be maintained for use
8
when necessary. Any supply of undesignated asthma medication
9
must be maintained in accordance with the manufacturer's
10
instructions.
11

A school district that provides special educational
12
facilities for children with disabilities under Section
13
14-4.01 of this Code may maintain a supply of undesignated
14
oxygen tanks in any secure location that is accessible before,
15
during, and after school where a person with developmental
16
disabilities is most at risk, including, but not limited to,
17
classrooms and lunchrooms. A physician, a physician assistant
18
who has prescriptive authority in accordance with Section 7.5
19
of the Physician Assistant Practice Act of 1987, or an
20
advanced practice registered nurse who has prescriptive
21
authority in accordance with Section 65-40 of the Nurse
22
Practice Act may prescribe undesignated oxygen tanks in the
23
name of the school district that provides special educational
24
facilities for children with disabilities under Section
25
14-4.01 of this Code to be maintained for use when necessary.
26
Any supply of oxygen tanks shall be maintained in accordance

SB2837
- 14 -
LRB104 17109 LNS 30528 b
1
with the manufacturer's instructions and with the local fire
2
department's rules.
3

(f-3) Whichever entity initiates the process of obtaining
4
undesignated epinephrine injectors and providing training to
5
personnel for carrying and administering undesignated
6
epinephrine injectors shall pay for the costs of the
7
undesignated epinephrine injectors.
8

(f-5) Upon any administration of an epinephrine injector,
9
a school district, public school, charter school, or nonpublic
10
school must immediately activate the EMS system and notify the
11
student's parent, guardian, or emergency contact, if known.
12

Upon any administration of an opioid antagonist, a school
13
district, public school, charter school, or nonpublic school
14
must immediately activate the EMS system and notify the
15
student's parent, guardian, or emergency contact, if known.
16

(f-10) Within 24 hours of the administration of an
17
undesignated epinephrine injector, a school district, public
18
school, charter school, or nonpublic school must notify the
19
physician, physician assistant, or advanced practice
20
registered nurse who provided the standing protocol and a
21
prescription for the undesignated epinephrine injector of its
22
use.
23

Within 24 hours after the administration of an opioid
24
antagonist, a school district, public school, charter school,
25
or nonpublic school must notify the health care professional
26
who provided the prescription for the opioid antagonist of its

SB2837
- 15 -
LRB104 17109 LNS 30528 b
1
use.
2

Within 24 hours after the administration of undesignated
3
asthma medication, a school district, public school, charter
4
school, or nonpublic school must notify the student's parent
5
or guardian or emergency contact, if known, and the physician,
6
physician assistant, or advanced practice registered nurse who
7
provided the standing protocol and a prescription for the
8
undesignated asthma medication of its use. The district or
9
school must follow up with the school nurse, if available, and
10
may, with the consent of the child's parent or guardian,
11
notify the child's health care provider of record, as
12
determined under this Section, of its use.
13

(g) Prior to the administration of an undesignated
14
epinephrine injector, trained personnel must submit to the
15
school's administration proof of completion of a training
16
curriculum to recognize and respond to anaphylaxis that meets
17
the requirements of subsection (h) of this Section. Training
18
must be completed annually. The school district, public
19
school, charter school, or nonpublic school must maintain
20
records related to the training curriculum and trained
21
personnel.
22

Prior to the administration of an opioid antagonist,
23
trained personnel must submit to the school's administration
24
proof of completion of a training curriculum to recognize and
25
respond to an opioid overdose, which curriculum must meet the
26
requirements of subsection (h-5) of this Section. The school

SB2837
- 16 -
LRB104 17109 LNS 30528 b
1
district, public school, charter school, or nonpublic school
2
must maintain records relating to the training curriculum and
3
the trained personnel.
4

Prior to the administration of undesignated asthma
5
medication, trained personnel must submit to the school's
6
administration proof of completion of a training curriculum to
7
recognize and respond to respiratory distress, which must meet
8
the requirements of subsection (h-10) of this Section.
9
Training must be completed annually, and the school district,
10
public school, charter school, or nonpublic school must
11
maintain records relating to the training curriculum and the
12
trained personnel.
At least one member of an athletic coach's
13
staff at the school and any athletic trainers at the school
14
must complete the training curriculum.

15

(h) A training curriculum to recognize and respond to
16
anaphylaxis, including the administration of an undesignated
17
epinephrine injector, may be conducted online or in person.
18

Training shall include, but is not limited to:
19

(1) how to recognize signs and symptoms of an allergic
20

reaction, including anaphylaxis;
21

(2) how to administer an epinephrine injector; and
22

(3) a test demonstrating competency of the knowledge
23

required to recognize anaphylaxis and administer an
24

epinephrine injector.
25

Training may also include, but is not limited to:
26

(A) a review of high-risk areas within a school and

SB2837
- 17 -
LRB104 17109 LNS 30528 b
1

its related facilities;
2

(B) steps to take to prevent exposure to allergens;
3

(C) emergency follow-up procedures, including the
4

importance of calling 9-1-1 or, if 9-1-1 is not available,
5

other local emergency medical services;
6

(D) how to respond to a student with a known allergy,
7

as well as a student with a previously unknown allergy;
8

(E) other criteria as determined in rules adopted
9

pursuant to this Section; and
10

(F) any policy developed by the State Board of
11

Education under Section 2-3.190.
12

In consultation with statewide professional organizations
13
representing physicians licensed to practice medicine in all
14
of its branches, registered nurses, and school nurses, the
15
State Board of Education shall make available resource
16
materials consistent with criteria in this subsection (h) for
17
educating trained personnel to recognize and respond to
18
anaphylaxis. The State Board may take into consideration the
19
curriculum on this subject developed by other states, as well
20
as any other curricular materials suggested by medical experts
21
and other groups that work on life-threatening allergy issues.
22
The State Board is not required to create new resource
23
materials. The State Board shall make these resource materials
24
available on its Internet website.
25

(h-5) A training curriculum to recognize and respond to an
26
opioid overdose, including the administration of an opioid

SB2837
- 18 -
LRB104 17109 LNS 30528 b
1
antagonist, may be conducted online or in person. The training
2
must comply with any training requirements under Section 5-23
3
of the Substance Use Disorder Act and the corresponding rules.
4
It must include, but is not limited to:
5

(1) how to recognize symptoms of an opioid overdose;
6

(2) information on drug overdose prevention and
7

recognition;
8

(3) how to perform rescue breathing and resuscitation;
9

(4) how to respond to an emergency involving an opioid
10

overdose;
11

(5) opioid antagonist dosage and administration;
12

(6) the importance of calling 9-1-1 or, if 9-1-1 is
13

not available, other local emergency medical services;
14

(7) care for the overdose victim after administration
15

of the overdose antagonist;
16

(8) a test demonstrating competency of the knowledge
17

required to recognize an opioid overdose and administer a
18

dose of an opioid antagonist; and
19

(9) other criteria as determined in rules adopted
20

pursuant to this Section.
21

(h-10) A training curriculum to recognize and respond to
22
respiratory distress, including the administration of
23
undesignated asthma medication, may be conducted online or in
24
person. The training must include, but is not limited to:
25

(1) how to recognize symptoms of respiratory distress
26

and how to distinguish respiratory distress from

SB2837
- 19 -
LRB104 17109 LNS 30528 b
1

anaphylaxis;
2

(2) how to respond to an emergency involving
3

respiratory distress;
4

(3) asthma medication dosage and administration;
5

(4) the importance of calling 9-1-1 or, if 9-1-1 is
6

not available, other local emergency medical services;
7

(5) a test demonstrating competency of the knowledge
8

required to recognize respiratory distress and administer
9

asthma medication; and
10

(6) other criteria as determined in rules adopted
11

under this Section.
12

(i) Within 3 days after the administration of an
13
undesignated epinephrine injector by a school nurse, trained
14
personnel, or a student at a school or school-sponsored
15
activity, the school must report to the State Board of
16
Education in a form and manner prescribed by the State Board
17
the following information:
18

(1) age and type of person receiving epinephrine
19

(student, staff, visitor);
20

(2) any previously known diagnosis of a severe
21

allergy;
22

(3) trigger that precipitated allergic episode;
23

(4) location where symptoms developed;
24

(5) number of doses administered;
25

(6) type of person administering epinephrine (school
26

nurse, trained personnel, student); and

SB2837
- 20 -
LRB104 17109 LNS 30528 b
1

(7) any other information required by the State Board.
2

If a school district, public school, charter school, or
3
nonpublic school maintains or has an independent contractor
4
providing transportation to students who maintains a supply of
5
undesignated epinephrine injectors, then the school district,
6
public school, charter school, or nonpublic school must report
7
that information to the State Board of Education upon adoption
8
or change of the policy of the school district, public school,
9
charter school, nonpublic school, or independent contractor,
10
in a manner as prescribed by the State Board. The report must
11
include the number of undesignated epinephrine injectors in
12
supply.
13

(i-5) Within 3 days after the administration of an opioid
14
antagonist by a school nurse or trained personnel, the school
15
must report to the State Board of Education, in a form and
16
manner prescribed by the State Board, the following
17
information:
18

(1) the age and type of person receiving the opioid
19

antagonist (student, staff, or visitor);
20

(2) the location where symptoms developed;
21

(3) the type of person administering the opioid
22

antagonist (school nurse or trained personnel); and
23

(4) any other information required by the State Board.
24

(i-10) Within 3 days after the administration of
25
undesignated asthma medication by a school nurse, trained
26
personnel, or a student at a school or school-sponsored

SB2837
- 21 -
LRB104 17109 LNS 30528 b
1
activity, the school must report to the State Board of
2
Education, on a form and in a manner prescribed by the State
3
Board of Education, the following information:
4

(1) the age and type of person receiving the asthma
5

medication (student, staff, or visitor);
6

(2) any previously known diagnosis of asthma for the
7

person;
8

(3) the trigger that precipitated respiratory
9

distress, if identifiable;
10

(4) the location of where the symptoms developed;
11

(5) the number of doses administered;
12

(6) the type of person administering the asthma
13

medication (school nurse, trained personnel, or student);
14

(7) the outcome of the asthma medication
15

administration; and
16

(8) any other information required by the State Board.
17

(j) By October 1, 2015 and every year thereafter, the
18
State Board of Education shall submit a report to the General
19
Assembly identifying the frequency and circumstances of
20
undesignated epinephrine and undesignated asthma medication
21
administration during the preceding academic year. Beginning
22
with the 2017 report, the report shall also contain
23
information on which school districts, public schools, charter
24
schools, and nonpublic schools maintain or have independent
25
contractors providing transportation to students who maintain
26
a supply of undesignated epinephrine injectors. This report

SB2837
- 22 -
LRB104 17109 LNS 30528 b
1
shall be published on the State Board's Internet website on
2
the date the report is delivered to the General Assembly.
3

(j-5) Annually, each school district, public school,
4
charter school, or nonpublic school shall request an asthma
5
action plan from the parents or guardians of a pupil with
6
asthma. If provided, the asthma action plan must be kept on
7
file in the office of the school nurse or, in the absence of a
8
school nurse, the school administrator. Copies of the asthma
9
action plan may be distributed to appropriate school staff who
10
interact with the pupil on a regular basis, and, if
11
applicable, may be attached to the pupil's federal Section 504
12
plan or individualized education program plan.
13

(j-10) To assist schools with emergency response
14
procedures for asthma, the State Board of Education, in
15
consultation with statewide professional organizations with
16
expertise in asthma management and a statewide organization
17
representing school administrators, shall develop a model
18
asthma episode emergency response protocol before September 1,
19
2016. Each school district, charter school, and nonpublic
20
school shall adopt an asthma episode emergency response
21
protocol before January 1, 2017 that includes all of the
22
components of the State Board's model protocol.
23

(j-15) (Blank).
24

(j-20) On or before October 1, 2016 and every year
25
thereafter, the State Board of Education shall submit a report
26
to the General Assembly and the Department of Public Health

SB2837
- 23 -
LRB104 17109 LNS 30528 b
1
identifying the frequency and circumstances of opioid
2
antagonist administration during the preceding academic year.
3
This report shall be published on the State Board's Internet
4
website on the date the report is delivered to the General
5
Assembly.
6

(k) The State Board of Education may adopt rules necessary
7
to implement this Section.
8

(l) Nothing in this Section shall limit the amount of
9
epinephrine injectors that any type of school or student may
10
carry or maintain a supply of.
11
(Source: P.A. 102-413, eff. 8-20-21; 102-813, eff. 5-13-22;
12
103-175, eff. 6-30-23; 103-196, eff. 1-1-24; 103-348, eff.
13
1-1-24; 103-542, eff. 7-1-24 (see Section 905 of P.A. 103-563
14
for effective date of P.A. 103-542); 103-605, eff. 7-1-24.)

Footer

Disclaimer

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.

Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.
Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn